Sight Sciences announced that multiple presentations on the OMNI Surgical System will be presented at the 2025 American Glaucoma Society (AGS) Annual Meeting in Washington, D.C. from Feb. 26 to March 1. These presentations will showcase new data on the clinical effectiveness and safety of OMNI across diverse patient populations, the company said in a press release. 

The data reinforces the safety and clinical effectiveness of OMNI in treating primary open-angle glaucoma (POAG) in adult patients. Several of the presentations will feature data curated by Verana Health. The data stems from a partnership between Verana Health and the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight). 

"This new data from the IRIS Registry provides valuable real-world insights into the performance of OMNI across diverse patient populations and disease severities," said Leon W. Herndon Jr., MD, Duke University, in the press release. "For example, our study showed that MIGS, including OMNI, when combined with cataract surgery in black patients, resulted in clinically and statistically significant reductions in IOP through 24 months as well as statistically significant reductions in medication through 36 months."

Results of a systematic literature review and meta-analysis of clinical, economic, and humanistic evidence of the OMNI Surgical System and its predecessors for the treatment of open-angle glaucoma (OAG) will also be presented.

"Our review and analysis highlighted the accumulation of data demonstrating the favorable efficacy and safety profiles of OMNI and its predecessors over periods up to 36 months," said Sameh Mosaed, MD, professor and chief of Glaucoma Division at the Gavin Herbert Eye Institute of the University of California, Irvine, in the press release. "These results position OMNI as a beneficial long-term treatment option for patients with OAG."

Paul Badawi, co-founder and CEO of Sight Sciences, also added, "The breadth of clinical data presented at AGS highlights the long-term safety and effectiveness of OMNI in a wide range of glaucoma patients, including diverse patient populations as well as patients with different disease severities. These new findings reflect our commitment to advancing glaucoma care and providing physicians with effective treatment options that ultimately benefit patients by reducing their dependence on medications and improving their quality of life."

Launched in 2014, the IRIS Registry has amassed over 851 million patient encounters and 80 million unique de-identified patients from more than 30 electronic health records and 15,000 ophthalmologists and other eyecare professionals across the United States.

According to Sight Sciences, OMNI enables an implant-free, ab interno minimally invasive glaucoma surgery (MIGS) procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with glaucoma.

Presentations featuring OMNI data at AGS include:

• Thursday, February 27, 8:00 AM – 9:00 AM EST: 
• Systematic Review and Meta-analysis of Clinical, Economic, and Humanistic Evidence for the Canaloplasty/Trabeculotomy Surgical System (CTSS) in Open-Angle Glaucoma Treatment
• Presenting author: Sameh Mosaed, MD, UC Irvine
  Location: Ambassador Room – This meta-analysis of 22 unique studies, including 2,379 eyes, concluded that OMNI and predecessor devices (CTSS) consistently reduced IOP and decreased the need for medication up to 36 months. The data also showed that both standalone and combined treatment effectively reduced IOP and medication use for up to 24 months.
  
  
• Thursday, February 27, 5:11 PM – 5:19 PM EST: 
• What's your sign? GEMINI 
• Presenting author: Mona Kaleem, MD, Johns Hopkins School of Medicine
  Location: Regency Ballroom – We are pleased that AGS has recognized our prospective GEMINI study as a landmark trial in glaucoma. This presentation is part of the Surgery Day Section 5: AGS/ASCRS Symposium "From Sea to Shining Sea" - Landmark Trials in the MIGS Revolution
  
  
• Friday, February 28, 8:00 AM – 9:00 AM EST:
• Standalone Canaloplasty and Trabeculotomy Outcomes for Phakic and Pseudophakic Eyes: An American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight) Analysis
• Presenting author: Mark Pyfer, MD, Northern Ophthalmic Associates
  Location: Ambassador Room – This study demonstrated that OMNI provided clinically and statistically significant IOP reductions in both phakic and pseudophakic eyes, with an increase in medication-free patients at 36 months.
• Ab Interno Minimally Invasive Glaucoma Surgery Effectiveness in Black Patients: IRIS Registry Study
• Presenting author: Leon W. Herndon Jr., MD, Duke University
  Location: Ambassador Room – This study showed that MIGS procedures, including OMNI, combined with cataract surgery in black patients, resulted in significant reductions in IOP and medication use.
• 36-Month Outcomes from the American Academy of Ophthalmology IRIS Registry (Intelligent Research in Sight): Standalone Canaloplasty and Trabeculotomy in Eyes with Mild, Moderate, and Severe Primary Open-Angle Glaucoma (POAG)
• Presenting author: Christine Funke, MD, Barnet Dulaney Perkin Eye Center
  Location: Ambassador Room – This study demonstrated clinically and statistically significant IOP reductions across all glaucoma severity levels (mild, moderate and severe) following standalone canaloplasty and trabeculotomy using the OMNI Surgical System.

Additionally, Sight Sciences will host a lunch symposium where leading experts will explore a pivotal question: Will You Wait or Act? The Crucial Choice in Combating Glaucoma with Interventional Treatment.

• Date and Time: 
• Saturday, March 1, 2025
• 1:00 PM – 2:15 PM EST
• Location: 
• AGS Diamond Theater
• Faculty: 
• Ike Ahmed, MD; John A. Moran Eye Center, Salt Lake City
• Reay H. Brown, MD; Atlanta Ophthalmology Associates, Atlanta
• Christine M. Funke, MD; Barnet Dulaney Perkins, Phoenix
• Zarmeena Vendal, MD; Westlake Eye Specialists, Austin, TX

To register or explore other Sight Sciences events at AGS, visit www.sightsciences.com/ags.

For hands-on demos and more events and information, stop by booth #48 during exhibit hours.